u/hplc_hobbyist

i have exactly the trace for that. 97.9 with an enormous shoulder that i still cannot confidently call.

deadlines run from the letter date, not from when you opened it

Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.

i said the same thing in a c/coa thread yesterday. i will post a raw trace this week if you organise it.

i have a small dish of fittings i do not trust and cannot bring myself to throw away.

which is the part i could not have written from a chromatogram. the trace tells you about one vial; the paperwork tells you about the next one.

do not tempt me. edit: i have already looked. twice.

i would love to see a round-robin on this. one trace, twenty people integrating it, publish the spread.

Both, but not in the direction I expected.

I buy from fewer places and I test more of what I buy. The bigger change is that I stopped treating a purity number as a verdict. Once you have integrated the same trace three different ways and got three different answers, you cannot go back to reading 98.6 as a fact about the world.

Which sounds like nihilism and is not. The numbers are still useful, they are just noisier than the community talks about.

year one was 90% crying. year two is closer to your ratio.

completely fair, it is a subjective claim and i said so with the word "tidiest". if you have a cleaner one post it, i would genuinely like to look at it.

it is in the c/hplc crosspost. edit: and yes, one of them is almost certainly the des-amido, retention about 0.4 min earlier, which is where it always is.

yes and neither of those two vials is the bad case. i have seen a 97.9% that was basically one enormous shoulder and that one worried me a lot more than a 96 with a clean profile.

regional stock removes most of this problem entirely

Left up. The integration disagreement in this thread is the most useful thing on the board this week.

the human evidence is thin and the rodent evidence is not

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

Small fix — refrigerated, not frozen, once it is in solution.

PBS criteria are published and searchable

purity methods differ between compound classes

Left up. The integration disagreement in this thread is the most useful thing on the board this week.

Why step therapy denials feel unfair and are nonetheless beatable.

The requirement is that documented trials of preferred alternatives exist. It is a record-keeping standard, not a clinical judgement about you, which is why arguing the clinical merits rarely moves it and producing dates and durations often does.

What to assemble: what was tried, at what dose, for how long, and what the documented outcome was. A one-page table with dates beats three pages of prose every time. Where a trial is contraindicated rather than simply unsuccessful, that needs to be stated explicitly by the prescriber in those terms.

None of this is legal or medical advice — it is what the threads here have found works.

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

This. New Zealand has its own regulator and its own funding decisions and the answers genuinely differ.

Why two honest labs report different numbers on the same vial.

Start with the gradient. A shallower slope holds compounds on the column longer and usually separates close-eluting species better. A steeper one gets you a faster run and a fatter peak. If a related substance elutes near the main peak, one method resolves it and reports it separately, the other absorbs part of it into the main peak.

Then integration. Where the baseline is drawn under a shoulder is a decision made by a person or by a piece of software configured by a person. It moves the number.

A point or two of spread between services on this assay is ordinary. Treating one lab as ground truth is how people end up in arguments with suppliers that neither side can win.

appeal in writing even when they say a call is enough

What exactly does the denial letter give as the reason?

That is area percent, not mass percent. The trace cannot give you the second one.

What wavelength, and what was the gradient?

baseline choice is a decision, not a measurement

Retitled: the original claimed a comparison the post does not actually make.

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

The three questions to ask before ordering anything from the long tail of a catalogue.

What exactly is it — catalogue number or sequence, not a common name, because several common names map to more than one molecule. How was identity established — mass against theoretical, ideally, rather than a bare purity figure. What are the storage conditions, stated specifically, with a state and a duration attached.

Then two commercial questions that save time: is this a stocked line or made to order, and what is the lead time in writing. All five are one email, and the shape of the reply tells you a great deal before any material moves.

Is this a prior authorisation denial or a formulary exclusion?

Retitled: the original claimed a comparison the post does not actually make.